Zacks Investment Research on MSN
Moderna stock jumps after FDA reverses course on flu shot
Shares of Moderna MRNA rose 6% on Wednesday after the company announced that the FDA agreed to review its regulatory filing seeking approval for its seasonal influenza vaccine, mRNA-1010. A final ...
Moderna advances messenger RNA platform technologies Therapeutics pipeline spans vaccines and disease targets nasdaq index ...
Moderna, Inc. has rallied nearly 60% year-to-date, aided by clinical data, confirmation of potential 2026 clinical readouts, and financial updates. MRNA's updated five-year phase 2b data for ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果